Sézary syndrome is a T cell malignancy that has been poorly characterized at the genome level. In this study, Kielet al. perform whole-genome analyses and identify mutations in the JAK–STAT pathway and show that primary cells are sensitive to JAK inhibitors.
- Mark J. Kiel
- Anagh A. Sahasrabuddhe
- Kojo S. J. Elenitoba-Johnson
